Naveen S Basappa
Overview
Explore the profile of Naveen S Basappa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrem N, Beltran-Bless A, Ghosh S, Tajzler C, Wood L, Kollmannsberger C, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941888
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium...
2.
Gupta M, Wells C, Regan M, Xie W, Navani V, Saliby R, et al.
Eur Urol Oncol
. 2025 Jan;
8(1):171-178.
PMID: 39743422
Background And Objective: Patients receiving immune checkpoint blockade (ICB) therapy may experience periods of prolonged disease control without a need for systemic therapy. Treatment-free survival (TFS) is an important measure...
3.
Soytas M, Dragomir A, Sawaya G, Hesswani C, Tanguay M, Finelli A, et al.
BJU Int
. 2024 Dec;
PMID: 39631366
Objective: To evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival....
4.
Graham J, Ahmad A, Basappa N, Bernhard J, Bhindi B, Bosse D, et al.
Can Urol Assoc J
. 2024 Nov;
18(11):E371-E386.
PMID: 39500366
No abstract available.
5.
Gotto G, Yip S, Shayegan B, OSullivan D, Wallis C, Basappa N, et al.
Can Urol Assoc J
. 2024 Oct;
19(1):E25-E35.
PMID: 39470659
Introduction: Treatment intensification beyond androgen deprivation therapy (ADT) has shown survival benefit in patients with metastatic castration-sensitive prostate cancer (mCSPC). There is a need to better understand how these novel...
6.
Robin G, Basappa N, North S, Ghosh S, Kolinsky M
Curr Oncol
. 2024 Sep;
31(9):5080-5087.
PMID: 39330003
Background: The management of advanced prostate cancer continues to evolve rapidly, particularly with the earlier use of survival-prolonging therapies in metastatic castration-sensitive prostate cancer (mCSPC). Though approved prior to the...
7.
Beaulieu C, Wu K, Fuzery A, Raizman J, Tsui A, Ye C, et al.
JACC Case Rep
. 2024 Sep;
29(16):102462.
PMID: 39295815
A patient with metastatic renal cell carcinoma on axitinib and pembrolizumab had elevated high-sensitivity cardiac troponin T and normal high-sensitivity cardiac troponin I with unremarkable cardiac investigations. A noncardiac cause...
8.
Park C, Moria F, Ghosh S, Wood L, Bjarnason G, Bhindi B, et al.
Curr Oncol
. 2024 Aug;
31(8):4704-4712.
PMID: 39195334
Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with...
9.
Saad E, Gebrael G, Semaan K, Eid M, Saliby R, Labaki C, et al.
Oncologist
. 2024 Apr;
29(8):699-706.
PMID: 38630540
Background: Current tobacco smoking is independently associated with decreased overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) treated with targeted monotherapy (VEGF-TKI). Herein, we assess the influence...
10.
Motzer R, Choueiri T, Hutson T, Rha S, Puente J, Lalani A, et al.
Eur Urol
. 2024 Apr;
86(1):4-9.
PMID: 38582713
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was...